A map of metabolic phenotypes in patients with myalgic encephalomyelitis/chronic fatigue syndrome.
Hoel, Fredrik, Hoel, August, Pettersen, Ina Kn et al. · JCI insight · 2021 · DOI
Quick Summary
This study examined the chemicals in the blood of 83 ME/CFS patients compared to 35 healthy people to understand how their bodies use energy differently. Researchers found that ME/CFS patients had common metabolic changes suggesting their bodies are working harder to produce energy and are using fats and proteins differently as fuel. Interestingly, patients also fell into different subgroups with distinct metabolic patterns, suggesting ME/CFS may involve different energy problems in different people.
Why It Matters
This study provides concrete biological evidence that ME/CFS involves real, measurable changes in how the body metabolizes energy—moving beyond the historical dismissal of the disease as psychological. Identifying distinct metabolic subtypes could eventually enable personalized treatment approaches and explains why different patients may respond differently to interventions. Understanding energy metabolism dysfunction as a potential driver of symptoms opens new avenues for targeted supportive therapies.
Observed Findings
Common metabolic changes in ME/CFS patients compatible with elevated energy strain and altered utilization of fatty acids and amino acids as fuel sources.
Identification of three distinct metabolic subsets within the patient group with heterogeneous metabolic profiles.
Two patient subsets showed characteristic patterns of deregulated energy metabolism linked to specific clinical profiles.
Changes were supported by independent blood analyses and showed associations with clinical patient characteristics.
Evidence consistent with exertion-triggered tissue hypoxia and subsequent systemic metabolic adaptation.
Inferred Conclusions
Elevated energy strain in ME/CFS may result from exertion-triggered tissue hypoxia leading to systemic metabolic dysfunction and compensation.
Metabolic dysfunction likely acts as a mediator of key ME/CFS symptoms and represents a potential target for supportive interventions.
ME/CFS patients exhibit distinct metabolic phenotypes suggesting heterogeneous underlying pathophysiology rather than a single unified metabolic defect.
Both common and context-dependent metabolic changes provide a biological framework for understanding ME/CFS pathophysiology.
Remaining Questions
What This Study Does Not Prove
This study does not prove that metabolic changes cause ME/CFS symptoms or that correcting these metabolic abnormalities will cure the disease—it shows correlation, not causation. The cross-sectional design cannot establish whether metabolic changes precede symptom onset or result from prolonged illness. The findings also do not indicate whether the identified metabolic phenotypes represent distinct disease mechanisms or vary along a continuum.